Hawkins HWKN Pharmaceutical — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Hawkins in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: Hawkins’s 10-K, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Hawkins's pharmaceutical — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Hawkins's pharmaceutical — revenue?
- Hawkins (HWKN) reported pharmaceutical — revenue of $8.32M in Q1 2026.
- How has Hawkins's pharmaceutical — revenue changed year-over-year?
- Hawkins's pharmaceutical — revenue increased by 15.1% year-over-year, from $7.23M to $8.32M.
- What is the long-term trend for Hawkins's pharmaceutical — revenue?
- Over 2 years (2024 to 2026), Hawkins's pharmaceutical — revenue has grown at a 16.5% compound annual growth rate (CAGR), from $20.55M to $27.87M.
- What does pharmaceutical — revenue mean?
- This metric represents the total gross sales generated from the company's pharmaceutical product line, encompassing specialized chemical ingredients and solutions for the healthcare and life sciences sectors. It serves as a key indicator of the company's ability to capture market share within the high-value pharmaceutical supply chain and reflects the segment's contribution to overall corporate top-line growth. Monitoring this figure helps investors assess the diversification of the revenue base beyond traditional industrial and water treatment chemical applications.